Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy

American Journal of Cardiology

Volumn 113, Issue 4, 2014, Pages 631-636

  Wang, Kang Ling ^a,b   Liu, Chia Jen ^a,b   Chao, Tze Fan ^a,b   Chen, Su Jung ^a,b   Wu, Cheng Hsueh ^a,b   Huang, Chi Ming ^b   Chang, Chun Chin ^a   Wang, Ko Fan ^a   Chen, Tzeng Ji ^a   Lin, Shing Jong ^a,b   Chiang, Chern En ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; PROPENSITY SCORE; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84895071329     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.10.043     Document Type: Article

References (20)

1. P.M. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, R. Peto, J. Armitage, and C. Baigent Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
2. C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, C. Reith, N. Bhala, R. Peto, E.H. Barnes, A. Keech, J. Simes, and R. Collins Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
3. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, S.R. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T.R. Pedersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K.K. Ray, and I. Ford Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
4. D. Preiss, S.R. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, D.D. Waters, D.A. DeMicco, P. Barter, C.P. Cannon, M.S. Sabatine, E. Braunwald, J.J. Kastelein, J.A. de Lemos, M.A. Blazing, T.R. Pedersen, M.J. Tikkanen, N. Sattar, and K.K. Ray Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis Jama 305 2011 2556 2564
5. K.L. Wang, C.J. Liu, T.F. Chao, C.M. Huang, C.H. Wu, S.J. Chen, T.J. Chen, S.J. Lin, and C.E. Chiang Statins, risk of diabetes, and implications on outcomes in the general population J Am Coll Cardiol 60 2012 1231 1238
6. P.M. Ridker, A. Pradhan, J.G. MacFadyen, P. Libby, and R.J. Glynn Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 571
7. D.D. Waters, J.E. Ho, S.M. Boekholdt, D.A. Demicco, J.J. Kastelein, M. Messig, A. Breazna, and T.R. Pedersen Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes J Am Coll Cardiol 61 2013 148 152
8. D.D. Waters, J.E. Ho, D.A. DeMicco, A. Breazna, B.J. Arsenault, C.C. Wun, J.J. Kastelein, H. Colhoun, and P. Barter Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials J Am Coll Cardiol 57 2011 1535 1545
9. A.J. Karter, D. Schillinger, A.S. Adams, H.H. Moffet, J. Liu, N.E. Adler, and A.M. Kanaya Elevated rates of diabetes in Pacific Islanders and Asian subgroups: The Diabetes Study of Northern California (DISTANCE) Diabetes Care 36 2013 574 579
10. T. Tillin, A.D. Hughes, J. Mayet, P. Whincup, N. Sattar, N.G. Forouhi, P.M. McKeigue, and N. Chaturvedi The relationship between metabolic risk factors and incident cardiovascular disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited) - a prospective population-based study J Am Coll Cardiol 61 2013 1777 1786
11. S.D. Anker, and J.J. McMurray Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials? Eur Heart J 33 2012 2764 2765
12. E.P. Navarese, A. Buffon, F. Andreotti, M. Kozinski, N. Welton, T. Fabiszak, S. Caputo, G. Grzesk, A. Kubica, I. Swiatkiewicz, A. Sukiennik, M. Kelm, S. De Servi, and J. Kubica Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus Am J Cardiol 111 2013 1123 1130
13. H.S. Kim, Y. Wu, S.J. Lin, C. Deerochanawong, R. Zambahari, L. Zhao, Q. Zhang, and P. Yan Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study Curr Med Res Opin 24 2008 1951 1963
14. S.M. Grundy Pre-diabetes, metabolic syndrome, and cardiovascular risk J Am Coll Cardiol 59 2012 635 643
15. G.A. Nichols, T.A. Hillier, and J.B. Brown Progression from newly acquired impaired fasting glucose to type 2 diabetes Diabetes Care 30 2007 228 233
16. E.S. Ford, G. Zhao, and C. Li Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence J Am Coll Cardiol 55 2010 1310 1317
17. A.J. Garber Hypertension and lipid management in prediabetic states J Clin Hypertens (Greenwich) 13 2011 270 274
18. R. Bitzur Diabetes and cardiovascular disease: when it comes to lipids, statins are all you need Diabetes Care 34 Suppl 2 2011 S380 S382
19. R.A. DeFronzo, and M. Abdul-Ghani Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose Am J Cardiol 108 2011 3B 24B
20. P.S. Sever, C.L. Chang, A.K. Gupta, A. Whitehouse, and N.R. Poulter The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K Eur Heart J 32 2011 2525 2532